Novartis AG

NVS

$141.28

Updated: 23/09/2026, 07:09:30

Market Cap

$268.53B

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

Stock valuation chart

One-year closing share-price history for NVS

Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

USD

NYSE

CEO: Vasant Narasimhan

Employees: 75,267

https://www.novartis.com

Asset Summaries

Latest generated summaries for NVS

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for NVS.

Share price: $141.28
Market cap: $268.53B
Exchange: NYSE
Currency: USD
CEO: Vasant Narasimhan
Employees: 75,267
IPO date: 07/11/1996
Beta: 0.459
Last dividend: $0.00
Day range: $139.96 – $142.93
52-week range: $121.57 – $170.46
1-day performance: 0.21%
1-year performance: 16.21%
Current drawdown (1Y): -17.12%
CIK: 0001114448
CUSIP: 66987V109
ISIN: US66987V1098
Created: 07/12/2025, 05:32:31
Last update: 23/09/2026, 07:09:30

Track Novartis AG with an AI analyst

See which prediction-market events move NVS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to NVS from your Railway `news_articles` table.

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

GlobeNewsWire • STOCK • 12/06/2026, 07:36:00

Novartis says rare muscle disease drug shows promise in early trial

Reuters • STOCK • 11/06/2026, 19:41:12

Novartis Reports Positive Data for Neuromuscular Disorder Drug

Zacks Investment Research • STOCK • 11/06/2026, 16:26:18

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

GlobeNewsWire • STOCK • 11/06/2026, 03:00:00

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

GlobeNewsWire • STOCK • 08/06/2026, 05:00:00

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

GlobeNewsWire • STOCK • 04/06/2026, 08:15:00

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

GlobeNewsWire • STOCK • 03/06/2026, 13:30:00

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

GlobeNewsWire • STOCK • 01/06/2026, 03:15:00

Experimental Novartis radiopharma drug shows promise in early study

Reuters • STOCK • 31/05/2026, 09:16:57

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

GlobeNewsWire • STOCK • 26/05/2026, 03:15:00

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

GlobeNewsWire • STOCK • 21/05/2026, 03:15:00

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

GlobeNewsWire • STOCK • 17/05/2026, 17:30:00